文|氨基观察并购是门玄学,一面是天堂,一面是地狱,诱惑着一个个显赫的名字走进去。最新步入“地狱”的,是艾伯维。11月11日,艾伯维宣布,去年底斥资87亿美元收购Cerevel得到的“王牌项目” emraclidine,未能在两项针对精神分裂症的II期研究中达到预期终点,这为其未来蒙上阴影。消息一出,艾伯维股价暴跌12.57%,一夜之间市值蒸发400多亿美元。曾经,这起并购是业界“楷模”。从第一次...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.